Compare Davita Inc (DVA) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs NIO Inc. — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while NIO Inc. trades at $3.46 (market cap $8.62B). The key difference: Davita Inc is the larger of the two by market cap, and Davita Inc is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and NIO Inc. for 81 Days on average.
| DVA | NIO | |
|---|---|---|
Market Cap | $11.29B | $8.62B |
Volume | 582,204 | 39,648,517 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $7.46 |
52-Week Low | $103.87 | $3.37 |
Typical Hold Time | 113 Days | 81 Days |
Enterprise Value | $24.01B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
NIO trades at $3.54, down 55% from its 52-week high, with a bearish technical signal despite recent earnings beats. The company shows improving revenue growth (2025: $87.5B) and narrowing losses (net margin: -17.8% in 2025 vs -34.5% in 2024), supported by a strategic battery-swap partnership with Geely. However, negative cash flow (-$10.9B in 2024) and high debt ($20.6B total debt) remain concerns.
The stock offers speculative upside to the $6.23 analyst target (76% potential) but faces significant execution risks in China's competitive EV market. Investors must weigh improving fundamentals against persistent profitability challenges and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
